nach oben

The European Journal of Health Economics

Erschienen in:

16.06.2022 | Original paper

Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis

verfasst von: Phatcharaphorn Chotnoppharatphatthara, Voratima Yoodee, Suthinee Taesotikul, Jirawit Yadee, Unchalee Permsuwan

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Transcatheter aortic valve implantation (TAVI) is a less invasive and costly treatment for patients with severe aortic stenosis (AS). This study aimed to systematically review the published literature focusing on economic evaluation of TAVI compared with other alternative treatments in AS populations.

Methods

A systematic review was conducted from inception until May 2021 using PubMed, Scopus, Web of science and Embase databases. The qualities of included studies were evaluated using Consolidated Health Economic Evaluation Reporting Standard (CHEERS) criteria. Data of costs, outcomes, incremental cost-effectiveness ratio (ICER) and willingness to pay were extracted. To compare results, ICERs were converted to the 2020 United States dollar (USD) rate.

Results

Of the 29 included cost-effectiveness studies, TAVI was cost-effective in all studies in the low-risk group (3/3), 77% of studies (7/9) in the intermediate-risk group, half of the studies (6/12) in the high-risk group, and 83% of studies (10/12) in the inoperable group. When adjusted to USD 2020, ICERs ranged from USD 2741 to 1027,674 USD per quality-adjusted life-year gained. The overall quality of the studies ranged from moderate to high.

Conclusions

TAVI is potentially a cost-effective alternative to surgical aortic valve replacement (SAVR) for patients with operable AS with low, intermediate or high risk compared with medical management (MM) for patients with inoperable AS. TAVI was associated with a significant gain in quality-adjusted life-years in almost all studies compared to either SAVR or MM. TAVI is a costly procedure; therefore, justifying its cost-effectiveness depends on the acceptable threshold in each country.

Nur mit Berechtigung zugänglich

Ancona, R., SC, P.: Epidemiology of aortic valve stenosis (AS) and of aortic valve incompetence (AI): is the prevalence of AS/AI similar in different parts of the world? J. Cardiol. Pract. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-18/epidemiology-of-aortic-valve-stenosis-as-and-of-aortic-valve-incompetence-ai (2020). Accessed 11 May 2021

Brennan, J.M., Edwards, F.H., Zhao, Y., O’Brien, S.M., Douglas, P.S., Peterson, E.D.: Long-term survival after aortic valve replacement among high-risk elderly patients in the United States: insights from the Society of Thoracic Surgeons Adult Cardiac Surgery Database, 1991 to 2007. Circulation 126(13), 1621–1629 (2012)CrossRefPubMed

Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., et al.: 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 43(7), 561–632 (2022)CrossRefPubMed

Otto, C.M., Nishimura, R.A., Bonow, R.O., Carabello, B.A., Erwin, J.P., 3rd., Gentile, F., et al.: 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143(5), e35–e71 (2021)PubMed

Leon, M.B., Smith, C.R., Mack, M., Miller, D.C., Moses, J.W., Svensson, L.G., et al.: Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 363(17), 1597–1607 (2010)CrossRefPubMed

Sakiyalak, P., Slisatkorn, W., Pornratanarangsi, S., Wongpraparut, N., Jakrapanichakul, D., Raksamani, K., et al.: Transcatheter aortic valve implantation (TAVI): first case in Thailand. J Med Assoc Thai. 95(1), 124–128 (2012)PubMed

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., et al.: Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16(2), 231–50 (2013)CrossRefPubMed

Hong, D., Si, L., Jiang, M., Shao, H., Ming, W.K., Zhao, Y., et al.: Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) Inhibitors: a systematic review. Pharmacoeconomics 37(6), 777–818 (2019)PubMed

Adarkwah, C.C., van Gils, P.F., Hiligsmann, M., Evers, S.M.: Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 16(4), 513–523 (2016)CrossRefPubMed

10.

Health Quality Ontario: Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment. Ontario Health Technol. Assess. Ser. 16(19), 1–94 (2016)

11.

Brecker, S., Mealing, S., Padhiar, A., Eaton, J., Sculpher, M., Busca, R., et al.: Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart 1(1), e000155 (2014)CrossRefPubMedPubMedCentral

12.

Doble, B., Blackhouse, G., Goeree, R., Xie, F.: Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. J Thorac Cardiovasc Surg. 146(1), 52-60.e3 (2013)CrossRefPubMed

13.

Fairbairn, T.A., Meads, D.M., Hulme, C., Mather, A.N., Plein, S., Blackman, D.J., et al.: The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Heart 99(13), 914–920 (2013)CrossRefPubMed

14.

Freeman, P.M., Protty, M.B., Aldalati, O., Lacey, A., King, W., Anderson, R.A., et al.: Severe symptomatic aortic stenosis: medical therapy and transcatheter aortic valve implantation (TAVI)-a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data. Open Heart 3(1), e000414 (2016)CrossRefPubMedPubMedCentral

15.

Gada, H., Agarwal, S., Marwick, T.H.: Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: outcomes of a decision-analytic model. Ann Cardiothorac Surg 1(2), 145–155 (2012)PubMedPubMedCentral

16.

Gada, H., Kapadia, S.R., Tuzcu, E.M., Svensson, L.G., Marwick, T.H.: Markov model for selection of aortic valve replacement versus transcatheter aortic valve implantation (without replacement) in high-risk patients. Am J Cardiol 109(9), 1326–1333 (2012)CrossRefPubMed

17.

Geisler, B.P., Huygens, S.A., Reardon, M.J., Van Mieghem, N., Kappetein, A.P., Osnabrugge, R.L.J., et al.: Cost-effectiveness and projected survival of self-expanding transcatheter versus surgical aortic valve replacement for high risk patients in a European setting: a Dutch analysis based on the corevalve high risk trial. Struct Heart 1(5–6), 267–74 (2017)CrossRef

18.

Hancock-Howard, R.L., Feindel, C.M., Rodes-Cabau, J., Webb, J.G., Thompson, A.K., Banz, K.: Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings. J Med Econ 16(4), 566–574 (2013)CrossRefPubMed

19.

Inoue, S., Nakao, K., Hanyu, M., Hayashida, K., Shibahara, H., Kobayashi, M., et al.: Cost-effectiveness of transcatheter aortic valve implantation using a balloon-expandable valve in Japan: experience from the Japanese pilot health technology assessment. Value Health Reg Issues 21, 82–90 (2020)CrossRefPubMed

20.

Murphy, A., Fenwick, E., Toff, W.D., Neilson, M.P., Berry, C., Uren, N., et al.: Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. Int J Technol Assess Health Care 29(1), 12–19 (2013)CrossRefPubMed

21.

Neyt, M., Van Brabandt, H., Devriese, S., Van De Sande, S.: A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open 2(3), e001032 (2012)

22.

Orlando, R., Pennant, M., Rooney, S., Khogali, S., Bayliss, S., Hassan, A., et al.: Cost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation. Health Technol Assess 17(33), 1–86 (2013)CrossRefPubMedPubMedCentral

23.

Reynolds, M.R., Lei, Y., Wang, K., Chinnakondepalli, K., Vilain, K.A., Magnuson, E.A., et al.: Cost-effectiveness of transcatheter aortic valve replacement with a self-expanding prosthesis versus surgical aortic valve replacement. J Am Coll Cardiol 67(1), 29–38 (2016)CrossRefPubMedPubMedCentral

24.

Reynolds, M.R., Magnuson, E.A., Lei, Y., Wang, K., Vilain, K., Li, H., et al.: Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol 60(25), 2683–2692 (2012)CrossRefPubMed

25.

Reynolds, M.R., Magnuson, E.A., Wang, K., Lei, Y., Vilain, K., Walczak, J., et al.: Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation 125(9), 1102–1109 (2012)CrossRefPubMed

26.

Simons, C.T., Cipriano, L.E., Shah, R.U., Garber, A.M., Owens, D.K., Hlatky, M.A.: Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 6(4), 419–428 (2013)CrossRefPubMed

27.

Watt, M., Mealing, S., Eaton, J., Piazza, N., Moat, N., Brasseur, P., et al.: Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 98(5), 370–376 (2012)CrossRefPubMed

28.

Baron, S.J., Wang, K., House, J.A., Magnuson, E.A., Reynolds, M.R., Makkar, R., et al.: Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Circulation 139(7), 877–888 (2019)CrossRefPubMed

29.

Geisler, B.P., Jørgensen, T.H., Thyregod, H.G.H., Pietzsch, J.B., Søndergaard, L.: Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention 15(11), e959–e967 (2019)CrossRefPubMed

30.

Goodall, G., Lamotte, M., Ramos, M., Maunoury, F., Pejchalova, B., de Pouvourville, G.: Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. J Med Econ. 22(4), 289–296 (2019)CrossRefPubMed

31.

Kodera, S., Kiyosue, A., Ando, J., Komuro, I.: Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. J Cardiol 71(3), 223–229 (2018)CrossRefPubMed

32.

Kuntjoro, I., Tay, E., Hon, J., Yip, J., Kong, W., Poh, K.K., et al.: Cost-effectiveness of transcatheter aortic valve implantation in intermediate and low risk severe aortic stenosis patients in Singapore. Ann Acad Med Singap 49(7), 423–433 (2020)CrossRefPubMed

33.

Ribera, A., Slof, J., Andrea, R., Falces, C., Gutierrez, E., Del Valle-Fernandez, R., et al.: Transfemoral transcatheter aortic valve replacement compared with surgical replacement in patients with severe aortic stenosis and comparable risk: cost-utility and its determinants. Int J Cardiol 1(182), 321–328 (2015)CrossRef

34.

Tam, D.Y., Hughes, A., Fremes, S.E., Youn, S., Hancock-Howard, R.L., Coyte, P.C., et al.: A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. J Thorac Cardiovasc Surg 155(5), 1978–88.e1 (2018)CrossRefPubMed

35.

Tam, D.Y., Hughes, A., Wijeysundera, H.C., Fremes, S.E.: Cost-effectiveness of self-expandable transcatheter aortic valves in intermediate-risk patients. Ann Thorac Surg 106(3), 676–683 (2018)CrossRefPubMed

36.

Tarride, J.E., Luong, T., Goodall, G., Burke, N., Blackhouse, G.: A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res 11, 477–486 (2019)CrossRefPubMedPubMedCentral

37.

Zhou, J., Liew, D., Duffy, S.J., Walton, A., Htun, N., Stub, D.: Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. Int J Cardiol 1(294), 17–22 (2019)CrossRef

38.

Zhou, J.Y., Liew, D., Duffy, S.J., Walton, A., Htun, N., Stub, D.: Cost-effectiveness of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis. Heart Lung Circ 30(4), 547–554 (2021)CrossRefPubMed

39.

Adams, D.H., Popma, J.J., Reardon, M.J., Yakubov, S.J., Coselli, J.S., Deeb, G.M., et al.: Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370(19), 1790–1798 (2014)CrossRefPubMed

40.

Leon, M.B., Smith, C.R., Mack, M.J., Makkar, R.R., Svensson, L.G., Kodali, S.K., et al.: Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374(17), 1609–1620 (2016)CrossRefPubMed

41.

Mack, M.J., Leon, M.B., Thourani, V.H., Makkar, R., Kodali, S.K., Russo, M., et al.: Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380(18), 1695–1705 (2019)CrossRefPubMed

42.

Smith, C.R., Leon, M.B., Mack, M.J., Miller, D.C., Moses, J.W., Svensson, L.G., et al.: Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364(23), 2187–2198 (2011)CrossRefPubMed

Titel: Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis
verfasst von: Phatcharaphorn Chotnoppharatphatthara
Voratima Yoodee
Suthinee Taesotikul
Jirawit Yadee
Unchalee Permsuwan
Publikationsdatum: 16.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 3/2023
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-022-01477-3

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Does health technology assessment compromise access to pharmaceuticals?

Making the rules make sense: valuation of constrained resources

Willingness to provide informal care to older adults in Germany: a discrete choice experiment

Impact of a diabetes disease management program on guideline-adherent care, hospitalization risk and health care costs: a propensity score matching study using real-world data

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

Reply to: making the rules make sense: valuation of constrained resources